Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Nieuwe overeenkomst met Solvay, cijfers 30 nov
Volgen
@ Jan Willem, Accsys gaat haar productie verdubbelen dus zal 40.000 m3/jaar erbij komen, deal met Solvay is een minimale afname van 76.000 m3 van 2016 tot 2020 dus over 5 jaar gemiddeld 76.000/5=15.200m3 en is dus een stuk minder dan de uitbreiding van de productie van Accsys. De productie uitbreiding zal dus niet volledig aan Solvay worden verkocht. Verder heb ik nergens vernomen dat er daadwerkelijk een proefinstallatie in gebruik is door Solvay. Als er al een proefinstallatie is, zal deze niet commercieel uit worden gebaat. Ik denk dan ook dat accoya tot nu toe altijd gewoon uit Arnhem vandaan is gekomen.
Iemand er al eens aan gedacht dat Solvay uiteindelijk Accsys zou kunnen/willen overnemen? 1 grote fabriek in Arnhem is dan efficiënter dan 2 kleinere..
Bedankt voor je schrijven Pieter11, Ik waardeer je mening zéér en tenslotte zijn we gewoon een forum waarin wij allen een betrekking met de hout veredelaar Accsys hebben . Wel blijf ik erbij dat Solvay het zonder buffer niet gaat redden in 2019, en is het volgens mij ook niet zo dat een mogelijke nieuwe fabriek met diezelfde installaties als Accsys gaat werken, het kan ook zijn dat er al in de productie techniek een veel modernere versie is ontstaan waarmee er bijvoorbeeld nu ook met volledige stammen gewerkt kan worden . Knappe koppen hebben ze heus voldoende bij Solvay . mvg Jan Willem .
Wouter139 schreef op 29 november 2015 11:52 :
Iemand er al eens aan gedacht dat Solvay uiteindelijk Accsys zou kunnen/willen overnemen? 1 grote fabriek in Arnhem is dan efficiënter dan 2 kleinere..
Natuurlijk wel Wouter139 . Hier ging het wat vreemd op de vrijdag . Mocht er in de eerste weken een wat rustiger verloop optreden, is het zelfs mogelijk dat een grootaandeelhouder gestopt is met het dumpen van aandelen en verboden praktijken (schoonmaakploeg) Maar ik weet écht niet te vertellen om welke het gaat . mvg Jan Willem .
Dat zou natuurlijk zo maar kunnen. Maat wat wat zijn de cijfers morgen? En welke koers krijgen we op de borden?
Top cijfers!! De update staat op de website
ja geweldig eindelijk kunnen we flink upupupup
30 November 2015 ACCSYS TECHNOLOGIES PLC (“Accsys” or “the Company”) INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2015 Accsys, the chemical technology group, focused on the acetylation of wood, today announces interim results for the consolidated group for the six months ended 30 September 2015. AIM: AXS NYSE Euronext Amsterdam: AXS Unaudited six Unaudited six months ended months ended Total Group Revenue Gross Profit Underlying EBITDA* Underlying loss before tax* Loss before tax Period end cash balance 30 Sept 2015 €26.3m €9.4m €1.3m €(0.1m) €(0.1m) €7.5m 30 Sept 2014 €21.8m €5.0m €(1.9m) €(3.1m) €(6.2m) €13.5m Change +21% +88% Improved168% Improved97% Improved98% *Underlying EBITDA and loss before tax are stated before exceptional items of €nil (2014: €3.1m) recorded in respect of arbitration relating to the Diamond Wood licence agreement. Highlights ? Improved manufacturing margin together with an increase in revenue attributable to licensing and business development activities resulted in first positive EBITDA since restructuring in 2010; ? Continued trend of revenue growth in the period, with revenue increasing by 21% to €26.3m; ? Manufacturing segment profitability continues to improve, recording EBITDA of €5.0m (2014: €3.1m) as a result of higher prices and improved efficiency; gross manufacturing profit margin increased from 23% to 30%; ? Strong balance sheet maintained with cash balance of €7.5m at 30 September 2015; ? Cash in-flow from operating activities (before changes in working capital) of €1.8m (2014: out-flow of €0.7m excluding exceptional items) as a result of improvement in profitability; ? New agreement with Solvay signed since period end, for licencing, marketing and manufacturing of Accoya, including fees and funding to allow expansion of Accsys manufacturing capacity; ? Agreed minimum 76,000m3 off-take commitment from Solvay over next five years; and ? Proposed Tricoya consortium negotiations have progressed, with detailed engineering and site feasibility studies undertaken. Paul Clegg, Chief Executive commented: “Our latest set of results confirms that our manufacturing process generates increasing returns, giving us greater confidence to progress with our objective of ensuring we maintain a share in new manufacturing capacity. Not only have we seen a significant improvement in profitability in the period, but a number of important strategic steps have been taken in respect of the proposed formation of the new Tricoya consortium and the relationship with Solvay, enabling us to ensure that the ever-increasing demand for our products can be met in the future.”
Ziet er goed uit allemaal. Ben benieuwd naar de conference call.
Chairman’s statement Overview It is encouraging to be presenting the first set of results that are EBITDA positive since our restructuring in 2010. Accsys continues to make incremental improvements in manufacturing profitability which has been achieved through margin management. We are also seeing significant strategic developments as we exploit the opportunity that exists for our products and technologies. Revenue increased by 21% to €26.3m in the period reflecting increased prices and an increase in revenue attributable to our licencing and business development activities. Sales volumes were relatively flat as some distributors managed their inventories following price increases that we implemented to improve our profitability and to help manage our capacity utilisation. The increase in prices contributed to the significant improvement in profitability giving rise to a positive EBITDA of €1.3m (2014: €1.9m loss). Improved prices and an on-going focus on operating efficiencies resulted in an improvement in gross manufacturing profit margin which increased from 23% to 30% and with manufacturing segment EBITDA increasing by 62% to €5.0m. The manufacturing profitability continues to indicate the returns which we believe are achievable when producing greater volumes. Our balance sheet remains strong, with a cash balance of €7.5m as at 30 September 2015 (€10.8m as at 31 March 2015). Underlying cash flows from operating activities before changes in working capital improved from a €0.7m out-flow to a €1.8m in-flow with the decrease in cash in the period attributable to an increase in working capital of €3.1m. This included a notable build-up of inventories ahead of our scheduled annual maintenance stop in October such that we expect cash-flow to benefit from a reduction in working capital in the second half of the financial year. We recently announced a new agreement with Solvay Acetow Gmbh (“Solvay”), to refine the relationship between the two parties for the licensing, marketing and manufacturing of Accoya®. This new agreement provides the framework and funding for a significant increase in the manufacturing capacity at our plant in Arnhem. The enhanced relationship with Solvay will benefit both parties, with the increased manufacturing capacity and resulting sales expected to be achieved for Accoya in a faster timescale than would otherwise have been possible. A combination of loans and fees from Solvay, in addition to those due under a new offtake commitment, will fund the majority of the initial increase in manufacturing capacity at Arnhem, with the balance to be met by Accsys’ own resources, including the possible sale and leaseback of land at Arnhem. Following the acquisition of the remaining 50% in Tricoya Technologies Limited (‘TTL’) in March 2015, and the agreement of a Memorandum of Understanding with a large international chemical group (the ‘Chemical Group’) we have continued to progress towards the creation of a new consortium to fund, build and operate the world’s first Tricoya® acetylation plant. In addition to detailed negotiations with the proposed consortium partners, which also include Medite, we have completed the Front End Engineering and Design (‘FEED’) study necessary to progress to the construction stage. Detailed discussions continue between the parties with an intention of finalising the consortium ahead of the plant becoming operational by 2018 however further work is expected to be jointly funded before final consortium agreements are put in place. ?3 Chairman’s statement Outlook The progress made with our key partners and the improvement in profitability represent significant developments for the Company as we continue towards our ambition of maximising the value associated with our technologies. In the immediate term we will continue to carefully manage the increasing demand for Accoya prior to additional capacity coming on stream in 2017, such that we expect revenue to continue to grow but at a smaller rate than that recorded in previous financial years. The new agreement with Solvay is particularly exciting and marks a significant step in the evolution of Accsys. It will enable us to significantly increase manufacturing capacity and to continue to develop markets on a global scale, whilst allowing us to take advantage of new opportunities and generate substantial group profits as production is ramped up. I am pleased with the progress being made in forming the proposed new Tricoya consortium and I am hopeful that the progress and efforts made by all of the proposed consortium partners will culminate in the new plant, further increasing manufacturing profits for the benefit of Accsys shareholders. Overall, I remain confident that we are in a strong position to continue our transition into a sustainable and profitable group focussed on commercialising our technologies through a balance of our own manufacturing capability and ongoing cooperation with strong industry partners. Patrick Shanley Chairman 27 November 2015
gelukzoeker69 schreef op 30 november 2015 08:23 :
ja geweldig eindelijk kunnen we flink upupupup
Dat moeten we maar afw8en of dat gebeurd!!
Chief Executive’s statement Solvay and new manufacturing capacity in Arnhem We recently announced details of a new agreement with Solvay Acetow Gmbh (“Solvay”), to refine the relationship between the two parties for the licensing, marketing and manufacturing of Accoya®. This new agreement provides the framework and funding for a significant increase in the manufacturing capacity in Arnhem. Solvay will purchase a minimum 76,000m3 of Accoya from the Arnhem plant over the period from 2016 to 2020 (the “offtake commitment”) and as a result of the increased manufacturing capacity in Arnhem and consequent greater sales capacity, under the new agreement Solvay will review the optimal timing to construct its 63,000 m3 Accoya manufacturing plant. The enhanced relationship with Solvay will benefit both parties, with the increased manufacturing capacity and resulting sales expected to be achieved for Accoya in a faster timescale than would otherwise have been possible. Accsys will double the existing manufacturing capacity at its Arnhem site in stages, up to 80,000m3 per annum from 40,000m3. The initial incremental 20,000m3 capacity is expected to come on stream in mid-2017. The licence agreement covering Europe has been amended to provide increased royalties to Accsys and the return to Accsys of the selling rights for more than 20 European countries. Accsys will provide sales and marketing services to Solvay on agreed terms in respect of Solvay’s exclusive European territories. A combination of loans and fees from Solvay, in addition to those due under the offtake commitment, will fund the majority of the initial increase in manufacturing capacity at Arnhem, with the balance to be met by Accsys’ own resources, including the possible sale and leaseback of land at Arnhem. These agreements allow the market development of Accoya to continue and optimise the roll out of manufacturing capacity under its partnering program with Solvay, increasing the certainty of supply for Accoya customers and users. It also enables Accsys to continue to develop global markets effectively, building on the expertise that it has developed over the last few years. Tricoya® Technologies Limited (‘TTL’) In March 2015 we announced our intention to form a consortium to fund, construct and then operate the world’s first Tricoya® chip acetylation plant, following Accsys’s acquisition of the remaining 50% share in TTL from our former joint venture partner, Ineos. Since then, we have progressed detailed discussions with the proposed consortium partners, being the Chemical Group, with whom we signed a Memorandum of Understanding (MoU) in March 2015, and Medite, TTL’s joint development partner since 2009. A site feasibility study has been undertaken to determine that the proposed plant can be located on one of the Chemical Group’s existing production sites, which is expected to provide significant operational and construction benefits to the consortium. TTL engaged an engineering house to complete the Front End Engineering and Design study which will enable the next stage of detailed design and construction to commence, immediately after the consortium is formally put in place. During this period, Medite Tricoya® has continued to be manufactured using Accoya sold by Accsys to Medite using a temporary process, pending construction of the dedicated Tricoya plant. However this has enabled sales of Medite Tricoya to grow, with sales volumes of Medite Tricoya panels increasing by 14% in the calendar year to October . Masisa, TTL’s licence option holder in Latin America, has also continued to progress its market development activities, with Masisa Tricoya XB being specified in an increasing number of projects. ?6 Accsys Technologies PLC Chief Executive’s statement Intellectual property Accsys has considerably increased its number of patent applications in the recent period by expanding its patent families to 22, including those relating to Tricoya®. Applications filed now number 191, filed in 43 countries. To date 42 patents have been granted in various countries throughout the world. Our principal trademark portfolio remains unchanged with our brands Accoya®, Tricoya®, the Trimarque device and Accsys®, including transliterations in Arabic, Chinese and Japanese, protected by registration in 56 countries. The Company’s patents and trademarks cover the products we and our distributors and licensees sell, and the processes by which these products are made, throughout the world. In addition to Accsys’s extensive patent and trade-mark portfolio, the Company continues to invest in the generation and protection of valuable know-how and confidential information relating to its products and processes, protected by way of confidentiality protocols and contractual agreements. Outlook We are pleased to be able to cement our relationship with Solvay to expand our Accoya manufacturing capacity and Solvay’s commitment to purchase significant volumes from Accsys over the coming years. This is an exciting step in the development of our business and is further evidence of the execution of our strategy to maximise returns from our technology platform and our innovative products. The proposed consortium with the Chemical Group and Medite, for the funding, construction and operation of the first Tricoya® chip acetylation plant is progressing well and I remain confident that Tricoya® remains a substantial and exciting opportunity for us. Both developments represent a way for Accsys to participate directly in the manufacture of higher volumes of our products than we have previously envisaged. I believe this model, where we seek to obtain a greater share of manufacturing margins while continuing to work with strong industry partners through licensing and joint venture activities puts us in a strong position to be able to grow shareholder value. In the immediate future, we will continue to carefully manage operations to ensure optimal management of our existing manufacturing capacity, working capital and costs such that we maintain sufficient resources to meet the demands of the next exciting period of our development. Paul Clegg Chief Executive 27 November 2015
Denk dat het heel belangrijk is dat er nu sprake is van cash in-flow van 1,8 miljoen
gelukzoeker69 schreef op 30 november 2015 08:23 :
ja geweldig eindelijk kunnen we flink upupupup
Je bent wel een gelukszoeker,maar upupup heb je nog niet gevonden.
Een vijfde meer omzet voor Accsys Gepubliceerd op 30 nov 2015 om 08:39 | Accsys 27 nov 0,99 0,00 (0,00%) AMSTERDAM (AFN) - Houtveredelaar Accsys heeft in de zes maanden tot en met eind september een omzet behaald van 26,3 miljoen euro. Dat is ruim een vijfde meer dan in dezelfde periode vorig jaar. De brutowinst verdubbelde bijna tot 9,4 miljoen euro, meldde de onderneming maandag. Het onderliggend bedrijfsresultaat (ebitda) kwam uit op 1,3 miljoen euro, tegen 1,9 miljoen euro negatief een jaar eerder. Accsys boekte nog wel een klein verlies voor belastingen, van 0,1 miljoen euro. Een jaar eerder kwam het tekort nog uit op 6,2 miljoen euro. - See more at: www.debeurs.nl/Beursnieuws/ANP-301115...
Accsys behaalt hogere omzet AMSTERDAM (Dow Jones)--Accsys Technologies plc (AXS.LN) heeft de afgelopen zes maanden de omzet zien stijgen en wist het resultaat te verbeteren, onder meer dankzij hogere licentie-inkomsten. De omzet over het eerste halfjaar van het gebroken boekjaar nam toe tot EUR26,3 miljoen van EUR21,8 miljoen een jaar terug. De onderliggende winst voor rente, belasting, afschrijving en amortisatie (EBITDA) verbeterde tot EUR1,3 miljoen positief van EUR1,9 miljoen negatief een jaar terug. Een verbetering van de marge en een toename van de inkomsten uit licenties resulteerden in de eerste positieve EBITDA sinds 2010, aldus Accsys. Dow Jones Nieuwsdienst; +31-20-5715200; amsterdam@dowjones.com (END) Dow Jones Newswires November 30, 2015 03:08 ET (08:08 GMT) *Binck is niet aansprakelijk voor informatie verschaft door derden
Heb nog niets gevonden over Diamond Wood, wellicht bij de conference call. De cijfers en toelichting zien er bemoedigend uit.
Cementwagen schreef op 30 november 2015 09:21 :
Heb nog niets gevonden over Diamond Wood, wellicht bij de conference call.
De cijfers en toelichting zien er bemoedigend uit.
alleen dat ze daar nog niet veel afzet hebben,lees orders, van DW,maar overall zeer mooi,going up to the next level...
Wow, goede cijfers en goede outlook. Ben benieuwd wat de koers gaat doen als london dadelijk opengaat.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)